A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes BOOST: INTENSIFY PREMIX/ALL 2
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BOOST
- Sponsors Novo Nordisk
- 10 Jul 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 15 Mar 2017 Planned End Date changed from 1 Jun 2017 to 21 Jun 2017.